Barts and the London School of Medicine and Dentistry, Centre for Endocrinology, John Vane Science Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Eur J Endocrinol. 2010 Feb;162(2):357-9. doi: 10.1530/EJE-09-0720. Epub 2009 Nov 10.
Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disease caused by ACTH resistance and leads to isolated glucocorticoid deficiency. Although FGD patients typically have normal mineralocorticoid secretion, subtle alterations in the renin-angiotensin-aldosterone axis have been reported in a subset of patients at presentation. Anecdotally, some patients with FGD have been initially diagnosed as having Addison's disease (AD), with implications for treatment and genetic counselling. Currently, mutations in three genes: the ACTH receptor (MC2R); the melanocortin 2 receptor accessory protein (MRAP); and the steroidogenic acute regulatory protein (STAR) are known to give rise to FGD types 1-3. We investigated a cohort of autoantibody-negative AD patients for mutations in these genes.
Forty patients with known AD without evidence of autoimmune disease were screened for mutations in MC2R, MRAP and STAR. In addition, patients were genotyped for the MC2R promoter polymorphism previously associated with reduced responsiveness to ACTH.
No mutations in MC2R, MRAP or STAR were identified in any patient. The frequencies of the MC2R promoter polymorphism were similar to those reported in healthy controls.
FGD does not appear to be underdiagnosed in the AD population. However, in approximately 50% of patients with FGD, no genetic cause has yet been identified and it is possible that the other, as yet unidentified, genes giving rise to FGD may be implicated in AD.
家族性糖皮质激素缺乏症(FGD)是一种罕见的常染色体隐性疾病,由 ACTH 抵抗引起,导致孤立性糖皮质激素缺乏。尽管 FGD 患者通常具有正常的盐皮质激素分泌,但在一些患者中,肾素-血管紧张素-醛固酮轴存在细微改变。据报道,一些 FGD 患者最初被诊断为艾迪生病(AD),这对治疗和遗传咨询有影响。目前,已知三个基因的突变:促肾上腺皮质激素受体(MC2R);黑素皮质素 2 受体辅助蛋白(MRAP);和类固醇急性调节蛋白(STAR)会导致 FGD 1-3 型。我们调查了一组自身抗体阴性的 AD 患者,以检测这些基因的突变。
对 40 名已知无自身免疫性疾病证据的 AD 患者进行 MC2R、MRAP 和 STAR 基因突变筛查。此外,对先前与 ACTH 反应性降低相关的 MC2R 启动子多态性进行了患者基因型分析。
在任何患者中均未发现 MC2R、MRAP 或 STAR 的突变。MC2R 启动子多态性的频率与健康对照组相似。
FGD 在 AD 人群中似乎并未被漏诊。然而,在大约 50%的 FGD 患者中,尚未确定遗传原因,并且可能存在其他尚未确定的导致 FGD 的基因与 AD 有关。